Crystal Pharmaceutical is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $7.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Crystal Pharmaceutical's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | FDA-approved 28 May 2024; first filer; FDA has not decided whether it keeps 180-day shared exclusivity | $7.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Crystal Pharmaceutical's share of it.
Crystal Pharmaceutical has FDA approval for Entresto, with no US launch confirmed. Of the 70 makers we follow, 38 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.